Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.
Kohei Shitara(National Cancer Center Hospital East), David H. Ilson(Memorial Sloan Kettering Cancer Center), Carles Pericay(University Hospital Mútua de Terrassa), Hisashi Hosaka(Gunma Prefectural Cardiovascular Center), María Alsina(Vall d'Hebron Hospital Universitari), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Özgür Özyılkan, Aziz Zaanan(Université Paris Cité), Sandra McGuigan(Taiho Oncology (United States)), Paula Jiménez‐Fonseca(Hospital Universitario Central de Asturias), Lukas Makris(DM-STAT (United States)), İrfan Çiçin(Istinye University), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Federico Longo(Instituto Cajal), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Armando Santoro(IRCCS Humanitas Research Hospital), Toshihiko Doi(National Cancer Center Hospital East), David Park(NYU Langone Health), Mohamedtaki Abdulaziz Tejani(AdventHealth Orlando)
Cited by 8
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821